DelveInsight’s ‘Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Relapsing-Remitting Multiple Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Relapsing-Remitting Multiple Sclerosis pipeline domain.
For Relapsing-Remitting Multiple Sclerosis emerging drugs, the Relapsing-Remitting Multiple Sclerosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report
- DelveInsight’s Relapsing-Remitting Multiple Sclerosis Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment.
- The leading Relapsing-Remitting Multiple Sclerosis companies include Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others are evaluating their lead assets to improve the Relapsing-Remitting Multiple Sclerosis treatment landscape.
- Key Relapsing-Remitting Multiple Sclerosis pipeline therapies in various stages of development include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
- In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.
Request a sample and discover the recent breakthroughs happening in the Relapsing-Remitting Multiple Sclerosis pipeline landscape @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook
Relapsing-Remitting Multiple Sclerosis Overview
Relapsing-Remitting Multiple Sclerosis (RRMS) is a common form of multiple sclerosis (MS), an autoimmune neurological disorder that affects the central nervous system. In RRMS, patients experience a pattern of unpredictable relapses, or exacerbations, followed by periods of remission where symptoms partially or completely subside. The exact cause of RRMS is not fully understood, but it is believed to result from a complex interplay of genetic, environmental, and immunological factors. In this condition, the immune system mistakenly attacks the protective myelin sheath that surrounds nerve fibers, leading to inflammation and damage. This disrupts the proper transmission of nerve signals, causing a range of symptoms.
Symptoms of RRMS can vary widely and may include fatigue, numbness or weakness in limbs, difficulty with coordination and balance, vision problems, pain, cognitive difficulties, and bladder or bowel dysfunction. The course of RRMS is characterized by periods of relapse, during which new or worsening symptoms appear, followed by periods of remission, where symptoms improve or stabilize. Diagnosing RRMS involves a combination of clinical evaluations, medical history analysis, and various diagnostic tests. Magnetic Resonance Imaging (MRI) is commonly used to visualize the presence of lesions on the brain and spinal cord, indicating the demyelination process. Cerebrospinal fluid analysis can also help identify specific markers related to the disease.
The management and treatment of RRMS focus on controlling symptoms, slowing down the disease progression, and reducing the frequency and severity of relapses. Disease-modifying therapies (DMTs) are a cornerstone of RRMS treatment, aiming to modify the immune response and reduce inflammation. These therapies can vary in their mechanisms and administration methods. Additionally, medications to manage specific symptoms such as pain, fatigue, and muscle spasms are also prescribed.
Find out more about Relapsing-Remitting Multiple Sclerosis medication @ New Drug for Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis Treatment Analysis: Drug Profile
IMU-838: Immunic AG
Vidofludimus calcium (IMU-838) is an investigational small molecule medication being developed as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), and other chronic inflammatory and autoimmune illnesses. Immunic believed that vidofludimus calcium, bolstered by excellent clinical data from the phase II EMPhASIS trial, has the potential to demonstrate medically significant advantages over other treatments, particularly for the early treatment of RMS patients, due to its placebo-like safety profile and robust anti-inflammatory and neuroprotective properties. The medication is now in Phase III development for the treatment of RRMS.
Tolebrutinib is a brain-penetrant Bruton’s tyrosine kinase inhibitor under research that obtains CSF concentrations required for targeting B lymphocytes and microglial cells. Tolebrutinib is being studied in Phase III clinical studies for the treatment of relapsing forms of multiple sclerosis (RMS), non-relapsing secondary progressive MS (nrSPMS), and primary progressive MS (PPMS), however, its safety and efficacy have yet to be determined by any regulatory authority globally.
Key Relapsing-Remitting Multiple Sclerosis Therapies and Companies
- IMU-838: Immunic
- Fenebrutinib: Roche
- Divozilimab: Biocad
- Vafidemstat: Oryzon Genomics
- Temelimab: GeNeuro SA
- Elezanumab: AbbVie
Learn more about the novel and emerging Relapsing-Remitting Multiple Sclerosis pipeline therapies @ Relapsing-Remitting Multiple Sclerosis Clinical Trials
Relapsing-Remitting Multiple Sclerosis Therapeutics Assessment
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Gene therapy
- Coverage: Global
- Key Relapsing-Remitting Multiple Sclerosis Companies: TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others.
- Key Relapsing-Remitting Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
Dive deep into rich insights for drugs used for Relapsing-Remitting Multiple Sclerosis treatment; visit @ Relapsing-Remitting Multiple Sclerosis Drugs
Table of Contents
|3.||Relapsing-Remitting Multiple Sclerosis Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics|
|6.||Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)|
|7.||Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)|
|8.||Relapsing-Remitting Multiple Sclerosis Pipeline: Mid-Stage Products (Phase II)|
|9.||Relapsing-Remitting Multiple Sclerosis Pipeline: Early Stage Products (Phase I)|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
For further information on the Relapsing-Remitting Multiple Sclerosis therapy in the pipeline, reach out @ Relapsing-Remitting Multiple Sclerosis Medication
Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.
Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.
Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.
Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.
Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.
Other Trending Reports
Acute Pharyngitis Market | Bartonellosis Market | Concussions Market Size | Allergic Rhinoconjunctivitis Market | Atherectomy Devices Market | Heavy Metal Poisoning Markets | Nipah Virus Infection Market | Central Venous Catheters Market | Encephalitis Market | Vertigo Market | Blood Glucose Monitoring Systems Market | Bone Anchored Hearing Systems Market | Non Alcoholic Fatty Liver Disease Nafld Market | Bipolar Depression Market | Rett Syndrome Market | Central Serous Chorioretinopathy Market | Prosthetic Joint Infection Market | Calciphylaxis Market | Metastatic Bone Pain Market | Postsurgical Pain Market | Acute Ocular Pain Market | Bacteremia Market | Cardiopulmonary Bypass Equipment Market | Chronic Pain Associated With Painful Diabetic Neuropathy Market | Generalized Pustular Psoriasis Market | Parkinsons Disease Related Dementia Market | Polypoidal Choroidal Vasculopathy Market | Progressive Familial Intrahepatic Cholestasis Market | Waiha Market | Atypical Hemolytic Uremic Syndrome Ahus Market | Egfr Non-small Cell Lung Cancer Market | Reactive Arthritis Market | Central Retinal Venous Occulsion Market | Age Related Vision Dysfunction Market | Atopic Keratoconjunctivitis Akc Market | Hyperinsulinemic Hypoglycemia Market | Thyroid Eye Disease Market | Diffuse Cutaneous Systemic Sclerosis Market | Arteriovenous Fistula Market | Acrocallosal Syndrome Market | Treatment Resistant Depression Market | Catheter-related Bloodstream Infections Market | Absssi Market | Anaphylaxis Market | Pressure Ulcers Market Size
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.